

Follow these steps to submit prior authorization requests when prescribing most drugs covered under the medical benefit for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members.

Note: The information below doesn't apply to oncology medical benefit drugs.

Michigan prescribers

To submit prior authorization requests electronically:

1. Log in to our provider portal (availability.com*).
2. Click *Payer Spaces* on the menu bar and click the BCBSM and BCN logo.
3. Click the *Medical and Pharmacy Benefit Drug Prior Auth* tile on the Applications tab.
4. In the Medical and Pharmacy Drug PA Portal, click the *Authorization* menu and select *Add New*.
5. Enter the member's last name, date of birth, subscriber ID and authorization start date.
6. Click *Search* and then select the appropriate member in the member list.
7. Complete all required fields and submit the request.

If you're registered for Availity Essentials™ but aren't able to access it, submit the prior authorization request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Non-Michigan prescribers

When submitting prior authorization requests, prescribers located outside of Michigan should complete the appropriate steps on the [Getting Started](#) page on **authorizations.bcbsm.com**. Look in the *Submit prior authorization requests* section.

If a non-Michigan prescriber is unable to submit a prior authorization request using the instructions on the webpage, submit the request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Information about the Medical and Pharmacy Drug PA Portal

To learn how to use the Medical and Pharmacy Drug PA Portal, view a recorded demo by going to Blue Cross and BCN's Provider Training site, searching on *drugs* and launching the *Medical and Pharmacy Drug Prior Auth portal overview mini module*.

For detailed information about accessing the Provider Training site, see the "Online training" section of the [Training Tools](#) page on **authorizations.bcbsm.com**.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

Medication Authorization Request Form
Saphnelo™ (anifrolumab-fnia) HCPCS CODE: J0491

This form is to be used by participating physicians to obtain coverage for Saphnelo™. For commercial members only, please complete this form and submit via fax to 877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION**PHYSICIAN INFORMATION**

Name

Name

ID Number

Specialty

D.O.B.

☐ Male ☐ Female

Address

Diagnosis

City /State/Zip

Drug Name

Phone/Fax: P: () - F: () -

Dose and Quantity

NPI

Directions

Contact Person

Date of Service(s)

Contact Person
Phone / Ext.**STEP 1:****DISEASE STATE INFORMATION**

1. Is this request for: ☐ Initiation ☐ Continuation **Date patient started therapy:** _____
2. Site of administration? ☐ Provider office/Home infusion ☐ Other: _____
☐ Hospital outpatient facility (go to #3) **Reason for Hospital Outpatient:** _____
3. Please specify location of administration if hospital outpatient infusion: _____
4. Please provide the NPI number for the place of administration: _____
5. **Initiation AND Continuation of therapy:**
 - a. Please check the patient's diagnosis: ☐ Systemic lupus erythematosus (SLE) ☐ Other: _____
 - b. Did the patient test positive for serum antibodies at 2 separate times?
☐ Yes, Positive test 1: _____ Date Drawn: _____
Positive test 2: _____ Date Drawn: _____
☐ No, Please list alternative test used to confirm diagnosis AND how it confirms the diagnosis: _____
 - c. Does the patient have active SLE?
☐ Yes, Please specify: _____ ☐ No
 - d. Does the patient have active lupus nephritis? ☐ Yes ☐ No
 - e. Does the patient have active central nervous system (CNS) lupus [for example: seizures, psychosis, stroke, cerebritis (infection of the brain)]?
☐ Yes ☐ No
 - f. Which of the following medications has the patient previously been treated with for a course of at least 12 weeks and failed?
☐ Chloroquine ☐ Hydroxychloroquine ☐ Methotrexate ☐ Azathioprine ☐ Cyclophosphamide ☐ Mycophenolate mofetil ☐ None
☐ Other: _____
 - g. Please select other medications the patient will be receiving while on Saphnelo:
☐ Antimalarials ☐ Corticosteroids ☐ Non-biologic immunosuppressives ☐ None ☐ Other: _____
 - h. Will the patient be using Saphnelo in combination with other biologics (for example: Benlysta)?
☐ Yes ☐ No
6. **Continuation request:** (please answer above questions as well): **Saphnelo start date:** _____
Have the patient's signs and symptoms improved while on Saphnelo?
☐ Yes
☐ No, Comment: _____
☐ Other: _____

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name

Physician Signature

Date

Step 2

Checklist

- ☐
- Form Completely Filled Out
-
- ☐
- Attached Chart Notes

- ☐
- ANA titer
-
- ☐
- Anti-dsDNA

- ☐
- SELENA-SLEDAI/BILAG score
-
- ☐
- Urine Analysis

Step 3

Submit

By Fax: BCBSM Specialty Pharmacy Mailbox
(877) 325-5979

By Mail: BCBSM Specialty Pharmacy Program
P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.

9/24/2021